Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy With Lemuteporfin in Subjects With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Sponsor: QLT Inc.
This PHASE2 trial investigates Prostatic Hyperplasia and is currently terminated or withdrawn. QLT Inc. leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
May 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- QLT Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Durham, United States
- • Garden City, United States
- • Greenbelt, United States
- • Lawrenceville, United States
- • San Antonio, United States
- • San Bernardino, United States
- • Shreveport, United States
- • Victoria, Canada
- • Virginia Beach, United States